Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/37087580http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/37087580http://www.w3.org/2000/01/rdf-schema#comment"

Objective

To investigate the changes of CD5L levels in patients with candidemia and explore the role of CD5L in progression of candidemia.

Methods

Twenty healthy control individuals, 27 patients with bacteremia and 35 patients with candidemia were examined for serum CD5L levels using ELISA, and the correlations of CD5L level with other serological indicators were analyzed. A C57BL/6 mouse model of candidemia induced by intravenous injection of Candida albicans were treated with intraperitoneal injection of recombinant CD5L protein, and renal histopathological and serological changes were analyzed to assess renal injures. The effects of CD5L treatment on general condition, fungal burden, of survival of the mice were observed, and the changes in serum IL-6 and IL-8 levels of the mice were detected using ELISA.

Results

CD5L levels were significantly elevated in patients with candidemia and positively correlated with WBC, BDG, Scr and PCT levels. The mouse model of candidemia also showed significantly increased serum and renal CD5L levels, and CD5L treatment significantly increased fungal burden in the renal tissue, elevated IL-6 and IL-8 levels in the serum and kidney, aggravated renal tissue damage, and reduced survival rate of candidemia mice.

Conclusion

Serum CD5L levels are increased in patients with candidemia, and treatment with CD5L aggravates candidemia in mouse models."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.org/dc/terms/identifier"doi:10.12122/j.issn.1673-4254.2023.03.05"xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Gao Z."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Hu J."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Guo W."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Wu X."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Yang M."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/author"Dong K."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/date"2023"xsd:gYear
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/name"Nan Fang Yi Ke Da Xue Xue Bao"xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/pages"368-374"xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/title"[CD5L is elevated in the serum of patients with candidemia and promotes disease progression in mouse models]."xsd:string
http://purl.uniprot.org/citations/37087580http://purl.uniprot.org/core/volume"43"xsd:string
http://purl.uniprot.org/citations/37087580http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/37087580
http://purl.uniprot.org/citations/37087580http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/37087580
http://purl.uniprot.org/uniprot/#_O43866-mappedCitation-37087580http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37087580
http://purl.uniprot.org/uniprot/#_Q9QWK4-mappedCitation-37087580http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/37087580
http://purl.uniprot.org/uniprot/O43866http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/37087580
http://purl.uniprot.org/uniprot/Q9QWK4http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/37087580